290 related articles for article (PubMed ID: 30101525)
21. Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors.
Hamdan R; Zhou Z; Kleinerman ES
Mol Cancer Ther; 2014 Feb; 13(2):483-91. PubMed ID: 24282276
[TBL] [Abstract][Full Text] [Related]
22. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
Iivanainen E; Lauttia S; Zhang N; Tvorogov D; Kulmala J; Grenman R; Salven P; Elenius K
Microvasc Res; 2009 Dec; 78(3):278-85. PubMed ID: 19596357
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of factor inhibiting HIF-1 enhances vessel maturation and tumor growth via platelet-derived growth factor-C.
Kuzmanov A; Wielockx B; Rezaei M; Kettelhake A; Breier G
Int J Cancer; 2012 Sep; 131(5):E603-13. PubMed ID: 22095574
[TBL] [Abstract][Full Text] [Related]
24. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression.
Tsioumpekou M; Cunha SI; Ma H; Åhgren A; Cedervall J; Olsson AK; Heldin CH; Lennartsson J
Theranostics; 2020; 10(3):1122-1135. PubMed ID: 31938055
[TBL] [Abstract][Full Text] [Related]
25. Endothelial-specific Notch blockade inhibits vascular function and tumor growth through an eNOS-dependent mechanism.
Patenaude A; Fuller M; Chang L; Wong F; Paliouras G; Shaw R; Kyle AH; Umlandt P; Baker JH; Diaz E; Tong J; Minchinton AI; Karsan A
Cancer Res; 2014 May; 74(9):2402-11. PubMed ID: 24599126
[TBL] [Abstract][Full Text] [Related]
26. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression.
Franco M; Roswall P; Cortez E; Hanahan D; Pietras K
Blood; 2011 Sep; 118(10):2906-17. PubMed ID: 21778339
[TBL] [Abstract][Full Text] [Related]
27. A differential role for CD248 (Endosialin) in PDGF-mediated skeletal muscle angiogenesis.
Naylor AJ; McGettrick HM; Maynard WD; May P; Barone F; Croft AP; Egginton S; Buckley CD
PLoS One; 2014; 9(9):e107146. PubMed ID: 25243742
[TBL] [Abstract][Full Text] [Related]
28. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
Kim SJ; Jung KH; Son MK; Park JH; Yan HH; Fang Z; Kang YW; Han B; Lim JH; Hong SS
Cancer Lett; 2017 Sep; 403():339-353. PubMed ID: 28688971
[TBL] [Abstract][Full Text] [Related]
29. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature.
Rybinski K; Imtiyaz HZ; Mittica B; Drozdowski B; Fulmer J; Furuuchi K; Fernando S; Henry M; Chao Q; Kline B; Albone E; Wustner J; Lin J; Nicolaides NC; Grasso L; Zhou Y
Oncotarget; 2015 Sep; 6(28):25429-40. PubMed ID: 26327620
[TBL] [Abstract][Full Text] [Related]
30. Olfactomedin-like 3 promotes PDGF-dependent pericyte proliferation and migration during embryonic blood vessel formation.
Imhof BA; Ballet R; Hammel P; Jemelin S; Garrido-Urbani S; Ikeya M; Matthes T; Miljkovic-Licina M
FASEB J; 2020 Nov; 34(11):15559-15576. PubMed ID: 32997357
[TBL] [Abstract][Full Text] [Related]
31. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
32. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
[TBL] [Abstract][Full Text] [Related]
33. Altered ratios of pro- and anti-angiogenic VEGF-A variants and pericyte expression of DLL4 disrupt vascular maturation in infantile haemangioma.
Ye X; Abou-Rayyah Y; Bischoff J; Ritchie A; Sebire NJ; Watts P; Churchill AJ; Bates DO
J Pathol; 2016 Jun; 239(2):139-51. PubMed ID: 26957058
[TBL] [Abstract][Full Text] [Related]
34. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
[TBL] [Abstract][Full Text] [Related]
35. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade.
Nisancioglu MH; Betsholtz C; Genové G
Cancer Res; 2010 Jun; 70(12):5109-15. PubMed ID: 20501841
[TBL] [Abstract][Full Text] [Related]
36. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis.
Guan YY; Luan X; Xu JR; Liu YR; Lu Q; Wang C; Liu HJ; Gao YG; Chen HZ; Fang C
Biomaterials; 2014 Mar; 35(9):3060-70. PubMed ID: 24393268
[TBL] [Abstract][Full Text] [Related]
37. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
Sumida T; Kitadai Y; Shinagawa K; Tanaka M; Kodama M; Ohnishi M; Ohara E; Tanaka S; Yasui W; Chayama K
Int J Cancer; 2011 May; 128(9):2050-62. PubMed ID: 21387285
[TBL] [Abstract][Full Text] [Related]
38. Possible Role and Therapeutic Target of PDGF-D Signalling in Colorectal Cancer.
Olsen RS; Dimberg J; Geffers R; Wågsäter D
Cancer Invest; 2019; 37(2):99-112. PubMed ID: 30836770
[TBL] [Abstract][Full Text] [Related]
39. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate.
Furuhashi M; Sjöblom T; Abramsson A; Ellingsen J; Micke P; Li H; Bergsten-Folestad E; Eriksson U; Heuchel R; Betsholtz C; Heldin CH; Ostman A
Cancer Res; 2004 Apr; 64(8):2725-33. PubMed ID: 15087386
[TBL] [Abstract][Full Text] [Related]
40. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
